Is there a role for statins in fungal infections?

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 12, 2013, Pages 1391-1400

  Bergman, Peter W ^a   Björkhem Bergman, Linda ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antifungal agents; Clinical studies; Drug interaction; Fungal infections; Statins

Indexed keywords

AMPHOTERICIN B; ATORVASTATIN; CASPOFUNGIN; FLUCONAZOLE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; MEVINOLIN; MICONAZOLE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; SURAMIN; TERBINAFINE;

ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ASPERGILLOSIS; CANDIDIASIS; CRYPTOCOCCAL MENINGITIS; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; FUNGAL METABOLISM; FUNGAL VIRULENCE; GROWTH INHIBITION; HOST PATHOGEN INTERACTION; HUMAN; HYDROPHILICITY; IMMUNOMODULATION; IN VITRO STUDY; INFECTION RISK; INFLAMMATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; CLINICAL TRIALS AS TOPIC; CULTURE MEDIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MYCOSES; PAECILOMYCES; RETROSPECTIVE STUDIES;

EID: 84888064390     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.856755     Document Type: Review

References (64)

1. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4(12), 977-987 (2005).
2. Bjorkhem-Bergman L, Acimovic J, Torndal UB, Parini P, Eriksson LC. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res. 30(4), 1105-1112 (2010).
3. Karp I, Behlouli H, Lelorier J, Pilote L. Statins and cancer risk. Am. J. Med. 121(4), 302-309 (2008).
4. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett. 260(1-2), 11-19 (2008).
5. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 7(6), 687-692 (2001).
6. Bordier BB, Ohkanda J, Liu P et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J. Clin. Invest. 112(3), 407-414 (2003).
7. Kistowska M, Rossy E, Sansano S et al. Dysregulation of the host mevalonate pathway during early bacterial infection activates human TCR gamma delta cells. Eur. J. Immunol. 38(8), 2200-2209 (2008).
8. Bjorkhem-Bergman L, Bergman P, Andersson J, Lindh, JD. Statin treatment and mortality in bacterial infections-a systematic review and meta-analysis. PLoS ONE 5(5), e10702 (2010).
9. Tsan YT, Lee CH, Ho WC, Lin MH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis C virus infection. J. Clin. Oncol. 31(12), 1514-1521 (2013).
10. Tsan YT, Lee CH, Wang JD, Chen PC. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Clin. Oncol. 30(6), 623-630 (2012).
11. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid. Res. 33(11), 1569-1582 (1992).
12. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19(1), 117-125 (2005).
13. Neuvonen PJ. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr. Opin. Investig. Drugs 11(3), 323-332 (2010).
14. Kitazawa E, Tamura N, Iwabuchi H et al. Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Biochem. Biophys Res. Commun. 192(2), 597-602 (1993).
15. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann. Pharmacother. 44(3), 507-514 (2010).
16. Galgoczy L, Nyilasi I, Papp T, Vagvolgyi C. Are statins applicable for the prevention and treatment of zygomycosis? Clin. Infect. Dis. 49(3), 483, author reply 84-85 (2009).
17. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56(3), 225-229 (2000).
18. Bergman P, Linde C, Putsep K et al. Studies on the antibacterial effects of statins-in vitro and in vivo. PLoS ONE 6(8), e24394 (2011).
19. Bjorkhem-Bergman L, Lindh JD, Bergman P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br. J. Clin. Pharmacol. 72(1), 164-165 (2011).
20. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. 54(5), 472-477 (2002).
21. Pan HY, DeVault AR, Wang-Iverson D, Ivashkiv E, Swanson BN, Sugerman AA. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J. Clin. Pharmacol. 30(12), 1128-1135 (1990).
22. Tse FL, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. J. Pharm. Sci. 82(9), 942-947 (1993).
23. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S. Molecular basis of resistance to azole antifungals. Trends Mol. Med. 8(2), 76-81 (2002).
24. Wilding EI, Brown JR, Bryant AP et al. Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J. Bacteriol. 182(15), 4319-4327 (2000).
25. Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci. Transl. Med. 4(165), 165rv13 (2012).
26. Netea MG, Brown GD. Fungal infections: the next challenge. Curr. Opin. Microbiol. 15(4), 403-405 (2012).
27. Larru B, Zaoutis TE. Newer antifungal agents. Curr. Opin. Pediatr. 25(1), 110-115 (2013).
28. Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am. J. Med. 125(1 Suppl.), S3-S13 (2012).
29. Bochar DA, Stauffacher CV, Rodwell VW. Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mol. Genet. Metab. 66(2), 122-127 (1999).
30. Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob. Agents Chemother. 50(1), 96-103 (2006).
31. Chin NX, Weitzman I, Della-Latta P. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41(4), 850-852 (1997).
32. Galgoczy L, Lukacs G, Nyilasi I, Papp T, Vagvolgyi C. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. Acta Biol. Hung. 61(3), 356-365 (2010).
33. Gyetvai A, Emri T, Takacs K et al. Lovastatin possesses a fungistatic effect against Candida albicans, but does not trigger apoptosis in this opportunistic human pathogen. FEMS Yeast Res. 6(8), 1140-1148 (2006).
34. Menezes EA, Vasconcelos Junior AA, Silva CL, Plutarco FX, Cunha Mda C, Cunha FA. In vitro synergism of simvastatin and fluconazole against Candida species. Rev. Inst. Med. Trop. Sao Paulo 54(4), 197-199 (2012).
35. Nash JD, Burgess DS, Talbert RL. Effect of fluvastatin and pravastatin, HMG-CoA reductase inhibitors, on fluconazole activity against Candida albicans. J. Med. Microbiol. 51(2), 105-109 (2002).
36. Natesan SK, Chandrasekar PH, Alangaden GJ, Manavathu EK. Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. iagn. Microbiol. Infect. Dis. 60(4), 369-373 (2008).
37. Nyilasi I, Kocsube S, Krizsan K et al. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol. Lett. 307(2), 175-184 (2010).
38. Qiao J, Kontoyiannis DP, Wan Z, Li R, Liu W. Antifungal activity of statins against Aspergillus species. Med. Mycol. 45(7), 589-593 (2007).
39. Song JL, Lyons CN, Holleman S, Oliver BG, White TC. Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med. Mycol. 41(5), 417-425 (2003).
40. Nyilasi I, Kocsube S, Pesti M, Lukacs G, Papp T, Vagvolgyi C. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J. Med. Microbiol. 59(Pt 2), 200-205 (2010).
41. Galgoczy L, Papp T, Vagvolgyi C. In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. Mycoses 52(5), 447-453 (2009).
42. Macreadie IG, Johnson G, Schlosser T, Macreadie PI. Growth inhibition of Candida species and Aspergillus fumigatus by statins. FEMS Microbiol. Lett. 262(1), 9-13 (2006).
43. Liu G, Vellucci VF, Kyc S, Hostetter MK. Simvastatin inhibits Candida albicans biofilm in vitro. Pediatr. Res. 66(6), 600-604 (2009).
44. Westermeyer C, Macreadie IG. Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata. FEMS Yeast Res. 7(3), 436-441 (2007).
45. Nyilasi I, Kocsube S, Krizsan K et al. Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations. Med. Mycol. doi:10.3109/13693786.2013.828160 (2013) (Epub ahead of print).
46. Thelen KM, Rentsch KM, Gutteck U et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J. Pharmacol. Exp. Ther. 316(3), 1146-1152 (2006).
47. Bjorkhem-Bergman L, Acimovic J, Torndal UB, Parini P, Eriksson LC. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res. 30(4), 1105-1112 (2010).
48. Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect. Dis. Clin. North Am. 20(3), 581-607, vi (2006).
49. Kontoyiannis DP. Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis. Clin. Infect. Dis. 44(8), 1089-1090 (2007).
50. Forrest GN, Kopack AM, Perencevich EN. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect. Dis. 10, 152 (2010).
51. Magulick JP, Frei CR, Ali SK et al. The effect of statin therapy on the incidence of infections: a retrospective cohort analysis. Am. J. Med. Sci. doi:10.1097/MAJ. 0b013e31828318e2 (2013) (Epub ahead of print).
52. Spanakis EK, Kourkoumpetis TK, Livanis G, Peleg AY, Mylonakis E. Statin therapy and decreased incidence of positive Candida cultures among patients with type 2 diabetes mellitus undergoing gastrointestinal surgery. Mayo Clin. Proc. 85(12), 1073-1079 (2010).
53. Thompson JN, Huycke MM, Greenfield RA, Kurdgelashvili G, Gentry CA. Case-control study of statin prevention of mould infections. Mycoses 54(5), e481-485 (2011).
54. Welch ML, Liappis AP, Kan VL. Candidemia outcomes not improved with statin use. Med. Mycol. 51(2), 219-222 (2013).
55. Dormuth CR, Patrick AR, Shrank WH et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 119(15), 2051-2057 (2009).
56. Jong A, Wu CH, Gonzales-Gomez I et al. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J. Biol. Chem. 287(19), 15298-15306 (2012).
57. Mira E, Leon B, Barber DF et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J. Immunol. 181(5), 3524-3534 (2008).
58. Jouneau S, Bonizec M, Belleguic C et al. Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. PLoS ONE 6(8), e22655 (2011).
59. Leal SM Jr, Roy S, Vareechon C et al. Targeting iron acquisition blocks infection with the fungal pathogens aspergillus fumigatus and fusarium oxysporum. PLoS Pathog. 9(7), e1003436 (2013).
60. Tashiro M, Kimura S, Tateda K et al. Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. Med. Mycol. 50(4), 353-360 (2012).
61. Galatti L, Mazzaglia G, Greco A et al. Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. Pharmacoepidemiol. Drug Saf. 16(4), 422-428 (2007).
62. Kahri J, Valkonen M, Backlund T, Vuoristo M, Kivisto KT. Rhabdomyolysis in a patient receiving atorvastatin and fluconazole. Eur. J. Clin. Pharmacol. 60(12), 905-907 (2005).
63. Nivoix Y, Ubeaud-Sequier G, Engel P, Leveque D, Herbrecht R. Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr. Drug Metab. 10(4), 395-409 (2009).
64. Chen Y, Zhang W, Huang WH et al. Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers. Eur. J. Clin. Pharmacol. (2013).